Print

Daxor Corporation (DXR) Announces Filing of Form N-2 and Seven Trial Agreements for the Daxor BVA-100 Blood Volume Analyzer  
6/29/2012 8:59:27 AM

NEW YORK, NY--(Marketwire - June 29, 2012) -

Daxor Corporation (NYSE MKT: DXR), a medical instrumentation and biotechnology company, has registered as an investment company. The Company filed a Form N-2 (Registration Statement Under the Investment Company Act of 1940) yesterday, June 28th.

Daxor has begun reporting as an investment company effective January 1, 2012. The Company filed a Form N-Q disclosing its schedule of portfolio holdings as of March 31, 2012.

The Company's next public report will be a Form N-CSR which will be for the six months ended June 30, 2012. This report will be filed with the SEC and sent to shareholders before the end of August 2012.

Since January 1, 2012, the Company has placed seven BVA-100 Blood Volume Analyzers on a trial basis in separate locations within the Continental United States. There are currently 65 Blood Volume Analyzers in service.

Daxor Corporation manufactures and markets the BVA-100, which is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website at www.Daxor.com.


Contact Information:
Daxor Corporation:
David Frankel
212-330-8504
(Chief Financial Officer)
dfrankel@daxor.com

Richard Dunn
212-330-8502
(Director of Operations)
rdunn@daxor.com

Diane Meegan
212-330-8512
(Investor Relations)
dmeegan@daxor.com


//-->